At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
GSK Biologicals HIV Vaccine 732462 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons
In Brief
A Phase 2 clinical trial evaluating GSK Biologicals HIV Vaccine 732462 and Placebo for AIDS. Completed, enrolled 191 participants across 42 sites in 4 countries.
Detailed Summary
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection. In HIV-1 infected persons who have not yet started antiretroviral therapy (ART), such a vaccine would potentially lead to a delay in the initiation of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAIDS
CountriesFrance, Germany, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionNov 2012
TodayJul 2026
First PostedOct 11, 2010
Enrollment StartNov 8, 2010
Primary CompletionNov 5, 2012
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 15.7 years ago
Interventions
GSK Biologicals HIV Vaccine 732462biological
2 or 3 doses according to protocol schedule
Placebodrug
1 or 3 doses according to protocol schedule